Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables (2017 - 2021)

Protagonist Therapeutics (PTGX) has disclosed Receivables for 5 consecutive years, with $1.6 million as the latest value for Q4 2021.

  • Quarterly Receivables fell 35.45% to $1.6 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2021, down 35.45% year-over-year, with the annual reading at $1.6 million for FY2021, 35.45% down from the prior year.
  • Receivables hit $1.6 million in Q4 2021 for Protagonist Therapeutics, down from $2.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.1 million in Q2 2021 to a low of $19000.0 in Q2 2017.
  • Historically, Receivables has averaged $2.7 million across 5 years, with a median of $2.4 million in 2018.
  • Biggest five-year swings in Receivables: surged 30684.21% in 2018 and later crashed 64.3% in 2019.
  • Year by year, Receivables stood at $1.9 million in 2017, then grew by 25.45% to $2.4 million in 2018, then crashed by 53.21% to $1.1 million in 2019, then surged by 120.55% to $2.4 million in 2020, then tumbled by 35.45% to $1.6 million in 2021.
  • Business Quant data shows Receivables for PTGX at $1.6 million in Q4 2021, $2.6 million in Q3 2021, and $7.1 million in Q2 2021.